The acetylcholinesterase reversible inhibitor N-octyl-1,2,3,4-tetrahydro-9-aminoacridine (THA-C8) is a new synthesized derivative of tacrine (THA) characterized by an alkyl chain in the molecular structure which ameliorates the penetrability of the compound into the central nervous system. THA-C8 (0.1-5 mg/kg) significantly reduced spontaneous locomotor activity in CD1 mice at a dose of 3 mg/kg. Moreover, THA-C8 (0.2-2 mg/kg) significantly improved shuttle-box avoidance acquisition at doses (0.25, 0.3, 1 mg/kg) not affecting locomotion and that are much lower than the doses reported to be effective for THA in animal models. From the data reported it seems that the new compound could be interesting for therapeutic purposes.
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Even if in recent years substantial progress has been made in the comprehension of Alzheimer's disease (AD) in several fields of investigation, we are still far from a therapy for this serious disease. A great number of data showing deficits in the activity of cholinergic enzymes and degeneration in cholinergic neurons in brains of AD patients support the well-known cholinergic hypothesis of AD (Bartus, Dean, Beer, & Lippa, 1982) that is, to date, the most extensively investigated. Attempts have been made to compensate for deficits in cholinergic transmission by treating AD patients with cholinomimetic agents. Among the several approaches to developing new drugs for ameliorating cognitive functions, special attention has been focused on tetrahydroaminoacridine (tacrine, THA) (Freeman & Dawson, 1991) , which was approved in 1991 by the U.S. Food and Drug Administration as a clinical strategy for AD (FDC Report, 1993) . This cholinesterase inhibitor has been reported to improve memory and learning deficits in animal models (Rupniak, Field, Samson, Steventon, & Iversen, 1990; Murray, Cross, & Green, 1991;  
